drugset / Trial / NCT01786135
A Safety Study of SGN-CD19A for B-Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
Timeline
- Start
- 2013-02
- Primary completion
- 2015-08
- Completion
- 2017-02-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | denintuzumab mafodotin | Unknown | — | Intravenous |